623 related articles for article (PubMed ID: 30128693)
1. SPECT and PET imaging in Alzheimer's disease.
Valotassiou V; Malamitsi J; Papatriantafyllou J; Dardiotis E; Tsougos I; Psimadas D; Alexiou S; Hadjigeorgiou G; Georgoulias P
Ann Nucl Med; 2018 Nov; 32(9):583-593. PubMed ID: 30128693
[TBL] [Abstract][Full Text] [Related]
2. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
Watanabe H
Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
[TBL] [Abstract][Full Text] [Related]
3. Novel PET/SPECT probes for imaging of tau in Alzheimer's disease.
Watanabe H; Ono M; Saji H
ScientificWorldJournal; 2015; 2015():124192. PubMed ID: 25879047
[TBL] [Abstract][Full Text] [Related]
4. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: novel PET/SPECT imaging probes for diagnosis of Alzheimer's disease.
Ono M; Saji H
J Pharmacol Sci; 2012; 118(3):338-44. PubMed ID: 22382657
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease: spect and pet tracers for beta-amyloid imaging.
Valotassiou V; Archimandritis S; Sifakis N; Papatriantafyllou J; Georgoulias P
Curr Alzheimer Res; 2010 Sep; 7(6):477-86. PubMed ID: 20455860
[TBL] [Abstract][Full Text] [Related]
6. [Current and future prospects of nuclear medicine in dementia].
Ito K; Inui Y; Kizawa T; Kimura Y; Kato T
Rinsho Shinkeigaku; 2017 Sep; 57(9):479-484. PubMed ID: 28804110
[TBL] [Abstract][Full Text] [Related]
7. In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings.
Hall B; Mak E; Cervenka S; Aigbirhio FI; Rowe JB; O'Brien JT
Ageing Res Rev; 2017 Jul; 36():50-63. PubMed ID: 28315409
[TBL] [Abstract][Full Text] [Related]
8. Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach.
Rodriguez-Vieitez E; Nordberg A
Methods Mol Biol; 2018; 1750():231-251. PubMed ID: 29512077
[TBL] [Abstract][Full Text] [Related]
9. PET and SPECT Radiotracers for Alzheimer's Disease.
Oukoloff K; Cieslikiewicz-Bouet M; Chao S; Da Costa Branquinho E; Bouteiller C; Jean L; Renard PY
Curr Med Chem; 2015; 22(28):3278-304. PubMed ID: 26242258
[TBL] [Abstract][Full Text] [Related]
10. Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future.
Ariza M; Kolb HC; Moechars D; Rombouts F; Andrés JI
J Med Chem; 2015 Jun; 58(11):4365-82. PubMed ID: 25671691
[TBL] [Abstract][Full Text] [Related]
11. Tau Positron Emission Tomography Imaging.
Kolb HC; Andrés JI
Cold Spring Harb Perspect Biol; 2017 May; 9(5):. PubMed ID: 27940517
[TBL] [Abstract][Full Text] [Related]
12. Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease.
Villemagne VL; Rowe CC; Macfarlane S; Novakovic KE; Masters CL
J Clin Neurosci; 2005 Apr; 12(3):221-30. PubMed ID: 15851069
[TBL] [Abstract][Full Text] [Related]
13. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.
Brier MR; Gordon B; Friedrichsen K; McCarthy J; Stern A; Christensen J; Owen C; Aldea P; Su Y; Hassenstab J; Cairns NJ; Holtzman DM; Fagan AM; Morris JC; Benzinger TL; Ances BM
Sci Transl Med; 2016 May; 8(338):338ra66. PubMed ID: 27169802
[TBL] [Abstract][Full Text] [Related]
14. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
15. Concordance between (99m)Tc-ECD SPECT and 18F-FDG PET interpretations in patients with cognitive disorders diagnosed according to NIA-AA criteria.
Ito K; Shimano Y; Imabayashi E; Nakata Y; Omachi Y; Sato N; Arima K; Matsuda H
Int J Geriatr Psychiatry; 2014 Oct; 29(10):1079-86. PubMed ID: 24687634
[TBL] [Abstract][Full Text] [Related]
16. Imaging discrepancies between magnetic resonance imaging and brain perfusion single-photon emission computed tomography in the diagnosis of Alzheimer's disease, and verification with amyloid positron emission tomography.
Yokoyama S; Kajiya Y; Yoshinaga T; Tani A; Hirano H
Psychogeriatrics; 2014 Jun; 14(2):110-7. PubMed ID: 24954834
[TBL] [Abstract][Full Text] [Related]
17. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
18. Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome.
Rafii MS
Dev Neurobiol; 2019 Jul; 79(7):711-715. PubMed ID: 30536948
[TBL] [Abstract][Full Text] [Related]
19. Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach.
Rodriguez-Vieitez E; Kumar A; Malarte ML; Ioannou K; Rocha FM; Chiotis K
Methods Mol Biol; 2024; 2785():195-218. PubMed ID: 38427196
[TBL] [Abstract][Full Text] [Related]
20. Amyloid imaging: Past, present and future perspectives.
Villemagne VL
Ageing Res Rev; 2016 Sep; 30():95-106. PubMed ID: 26827784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
